SCHEMBL4775748

SCHEMBL4775748

N#Cc1cc(Nc2ccc(Cl)cc2)c2cc(F)ncc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 4/20 0.45
SLC2A1 P11166 1/20 0.42
EHMT2 Q96KQ7 1/20 0.40
SRC P12931 1/20 0.39
MAP2K1 Q02750 1/20 0.38
ACP1 P24666 1/20 0.37
ABCB1 P08183 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
KCNH3 Q9ULD8 1/20 0.35
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
CDK4 P11802 1/20 0.34
CCND3 P30281 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776048 0.90 NPC1 (0.41) MAPKAPK2ACP1ABCB1ABCG2PTGS1
SCHEMBL4767004 0.88 ABCG2 (0.43) MAP2K1ACP1ABCB1ABCG2GAA
SCHEMBL4769765 0.88 SLC2A1 (0.42) MAPKAPK2SLC2A1ACP1ABCB1ABCG2
SCHEMBL4776121 0.88 KCNQ3 (0.39) MAPKAPK2ABCB1ABCG2PTGS2MAPT
SCHEMBL4777976 0.87 FADS1 (0.43) PTGS1PTGS2CNR2EGFR
SCHEMBL4766924 0.82 ABCB1 (0.39) SRCMAP2K1ACP1ABCB1ABCG2
SCHEMBL4769773 0.82 MAP2K1 (0.44) MAPKAPK2SRCMAP2K1ACP1ABCB1
SCHEMBL4768795 0.77 CYP11B2 (0.38)
SCHEMBL4767045 0.76 MAP2K1 (0.46) MAP2K1ACP1ABCB1ABCG2EGFR
SCHEMBL4775921 0.75 SRC (0.64) SRCMAP2K1EGFRSTK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432279-B2 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2008-10-07 US disclosed
EP-1881981-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-01-30 EP disclosed
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-12-07 US disclosed
WO-2006124944-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CNKSR1, DTYMK MAPKAPK2 94/4885SLC2A1 4126/4885EHMT2 2876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.